Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFIRINOX + Panitumumab vs mFOLFOX6 + Panitumumab in Metastatic Colorectal Cancer
NCT02980510Phase 2Completed
- Sponsor
- Unicancer
- Start
- Dec 2016
- Primary completion
- Dec 2025
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in metastatic colorectal cancer (mCRC) (2 arms), sponsored by Unicancer. Primary endpoint: Complete Response Rate at 12 months. Started Dec 2016; status: completed.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT02980510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02980510.